ORIC Pharmaceuticals Q2 EPS $(0.50) Up From $(0.51) YoY
Portfolio Pulse from Benzinga Newsdesk
ORIC Pharmaceuticals reported Q2 losses of $(0.50) per share, a 1.96% increase over losses of $(0.51) per share from the same period last year.
August 10, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ORIC Pharmaceuticals reported a slight improvement in its Q2 losses compared to the same period last year.
ORIC Pharmaceuticals reported a slight improvement in its Q2 losses, which could be seen as a positive sign by investors. However, the company is still reporting losses, which could limit the positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100